Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | +8.39% | +3.53% | -16.75% |
04-18 | Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board | CI |
03-12 | Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 103M 141M |
---|---|---|---|---|---|
Net income 2024 * | -14M -19.14M | Net income 2025 * | -15M -20.5M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.34
x | P/E ratio 2025 * |
-7.18
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.1% |
Latest transcript on Anixa Biosciences, Inc.
1 day | +8.39% | ||
1 week | +3.53% | ||
Current month | +3.53% | ||
3 months | -26.26% | ||
6 months | +6.25% | ||
Current year | -16.75% |
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 16-10-31 |
Pamela Garzone
PRN | Corporate Officer/Principal | 69 | 21-09-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 99-06-30 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 19-10-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.23 | +8.39% | 237,328 |
24-04-25 | 2.98 | -6.29% | 251,933 |
24-04-24 | 3.18 | +3.58% | 357,353 |
24-04-23 | 3.07 | +1.99% | 73,542 |
24-04-22 | 3.01 | -3.53% | 57,975 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.75% | 103M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ANIX Stock